10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents

Anders M. Galløe, Henning Kelbæk, Leif Thuesen, Henrik S Hansen, Jan Ravkilde, Peter R Hansen, Evald H Christiansen, Ulrik Abildgaard, Ghita B Stephansen, Jens F Lassen, Thomas Engstrøm, Jan Skov Jensen, Jørgen L Jeppesen, Niels Bligaard, SORT OUT II Investigators

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

BACKGROUND: First-generation drug-eluting coronary stents (DES) were introduced in 2003 to 2004, and their use resulted in a considerable reduction in the development of in-stent restenosis at the cost of an increased risk of late stent thromboses.

OBJECTIVES: This study followed clinical outcomes of patients included in a large randomized trial for 10 years to enable detection of late changes in annual event rates that could necessitate medical attention.

METHODS: A total of 2,098 unselected all-comer patients (50% with acute coronary syndrome) were randomly assigned to have a first-generation DES implanted. This study recorded the occurrence of a major adverse cardiac event (MACE) assessed as the composite of cardiac death, myocardial infarction, and target vessel revascularization. Stent thromboses were also assessed.

RESULTS: Of the 2,098 unselected patients, 73.1% were still alive after 10 years. During the follow-up period, MACE occurred in 346 (32.5%) in the group receiving a sirolimus-eluting stent and in 342 (33.1%) in the group receiving a paclitaxel-eluting stent (hazard ratio: 0.96; 95% confidence interval: 0.83 to 1.11; p = 0.60), with a steady annual rate of 2.6% after the first year. Definite, probable, and possible stent thrombosis appeared in 279 patients (13.3%), with no difference between stent types and with a steady annual rate of 1.3% after the first year.

CONCLUSIONS: Among the surviving patients, the long-term annual MACE rate and the stent thrombosis rate appeared constant for both stent types, with no apparent late changes. Although there is no need for extraordinary medical attention for these patients, the absence of declines in annual event rates calls for continuous surveillance. (Danish Organization on Randomized Trials With Clinical Outcome II [SORT OUT II]; NCT00388934).

Original languageEnglish
JournalJournal of the American College of Cardiology
Volume69
Issue number6
Pages (from-to)616-624
ISSN0735-1097
DOIs
Publication statusPublished - 2017

    Fingerprint

Keywords

  • Journal Article

Cite this

Galløe, A. M., Kelbæk, H., Thuesen, L., Hansen, H. S., Ravkilde, J., Hansen, P. R., Christiansen, E. H., Abildgaard, U., Stephansen, G. B., Lassen, J. F., Engstrøm, T., Jensen, J. S., Jeppesen, J. L., Bligaard, N., & SORT OUT II Investigators (2017). 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. Journal of the American College of Cardiology, 69(6), 616-624. https://doi.org/10.1016/j.jacc.2016.11.055